We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Prelude Therapeutics Inc | NASDAQ:PRLD | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.34 | -8.35% | 3.73 | 3.03 | 4.06 | 4.04 | 3.69 | 4.04 | 53,753 | 05:00:02 |
Details are as follows: On Wednesday, June 7th, at 8:00 a.m. ET, Kris Vaddi, Ph.D., CEO of Prelude will participate in a fireside chat. The live webcast is available here and will be available for replay for 90 days.
Dr. Vaddi, joined by Jane Huang, MD, President and Chief Medical Officer and Laurent Chardonnet, Chief Financial Officer, will host one-on-one meetings on June 7th.
About Prelude
Prelude is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. Prelude’s diverse pipeline is comprised of highly differentiated, potentially best-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for cancers with selectable underserved patients. Prelude’s pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and highly selective CDK9 inhibitor; PRT3645, a brain penetrant CDK4/6 inhibitor; and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
For more information, visit our website and follow us on LinkedIn and Twitter.
Investor Contact:Lindsey TrickettVice President, Investor Relations240.543.7970ltrickett@preludetx.com
Media Contact:Helen Shik Shik Communications 617.510.4373 Helen@ShikCommunications.com
1 Year Prelude Therapeutics Chart |
1 Month Prelude Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions